Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Accumulated Expenses (2020 - 2025)

Rani Therapeutics Holdings has reported Accumulated Expenses over the past 6 years, most recently at $46000.0 for Q4 2025.

  • Quarterly results put Accumulated Expenses at $46000.0 for Q4 2025, down 95.06% from a year ago — trailing twelve months through Dec 2025 was $46000.0 (down 95.06% YoY), and the annual figure for FY2025 was $46000.0, down 95.06%.
  • Accumulated Expenses for Q4 2025 was $46000.0 at Rani Therapeutics Holdings, down from $2.1 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for RANI hit a ceiling of $4.4 million in Q3 2022 and a floor of $46000.0 in Q4 2025.
  • Median Accumulated Expenses over the past 5 years was $2.4 million (2024), compared with a mean of $2.3 million.
  • Biggest five-year swings in Accumulated Expenses: soared 197.44% in 2024 and later plummeted 95.06% in 2025.
  • Rani Therapeutics Holdings' Accumulated Expenses stood at $1.4 million in 2021, then crashed by 62.48% to $538000.0 in 2022, then plummeted by 41.82% to $313000.0 in 2023, then soared by 197.44% to $931000.0 in 2024, then plummeted by 95.06% to $46000.0 in 2025.
  • The last three reported values for Accumulated Expenses were $46000.0 (Q4 2025), $2.1 million (Q3 2025), and $2.6 million (Q2 2025) per Business Quant data.